Thalidomide increases cytochrome P450 activity and drug metabolism in liver through direct activation of nuclear receptor CAR and PXR
沙利度胺通过直接激活核受体 CAR 和 PXR 增加肝脏细胞色素 P450 活性和药物代谢
基本信息
- 批准号:23590200
- 负责人:
- 金额:$ 3.49万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2011
- 资助国家:日本
- 起止时间:2011 至 2013
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
We demonstrated heterotropic cooperativity of human cytochrome P450 (P450) 3A4/5 by the teratogen thalidomide using a model substrate midazolam in various in vitro and in vivo models. Chimeric mice with humanized liver displayed enhanced midazolam clearance upon pre-treatment with orally administered thalidomide, presumably because of human P450 3A induction. Thalidomide enhanced levels of P450 3A4/2B6 mRNA, protein expression, and/or oxidation activity in human hepatocytes indirectly suggesting activation of gene transcription factors. Thalidomide and its human proportionate metabolite 5-hydroxythalidomide displayed significant modulation of coregulator interaction with CAR and PXR ligand-binding domains similar to established agonists for these receptors. These results collectively suggest that thalidomide could act as a ligand for PXR and CAR and cause enzyme induction. The possibilities of drug interactions during thalidomide therapy in humans should be evaluated further.
我们使用模型底物咪达唑仑在各种体外和体内模型中使用模型底物咪达唑仑证明了人类细胞色素P450(P450)3A4/5的异型合作。用人源化肝脏的嵌合小鼠在用口服的沙利度胺预处理后显示出增强的咪达唑仑清除率,这可能是由于人类P450 3A诱导。沙利度胺增强了人类肝细胞中P450 3A4/2B6 mRNA,蛋白质表达和/或氧化活性间接地表明基因转录因子的激活。沙利度胺及其人类比例代谢产物5-羟基乙油脂酰胺显示出与CAR和PXR配体结合结构域的重大调节,类似于这些受体的既定激动剂。这些结果共同表明沙利度胺可以充当PXR和CAR的配体,并引起酶诱导。应进一步评估人类沙利度胺治疗期间药物相互作用的可能性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Plasma concentrations of melengestrol acetate in humans extrapolated from the pharmacokinetics established in in vivo experiments with rats and chimeric mice with humanized liver and physiologically based pharmacokinetic modeling
根据大鼠和嵌合小鼠体内实验建立的人源化肝脏和基于生理学的药代动力学模型建立的药代动力学推断出醋酸美仑孕酮在人体内的血浆浓度
- DOI:10.1016/j.yrtph.2013.01.008
- 发表时间:2013
- 期刊:
- 影响因子:0
- 作者:Tsukada;A.;Suemizu;H.;Murayama;N.;Takano;R.;Shimizu;M.;Nakamura;M.;and Yamazaki;H
- 通讯作者:H
Acrylonitrile concentrations hypothetically modeled in humans
假设模拟人体丙烯腈浓度
- DOI:
- 发表时间:2013
- 期刊:
- 影响因子:0
- 作者:竹内裕紀;菊池祐紀子;平野俊彦;岩本整;中村有紀;今野理;城島嘉麿;木原優;横山卓剛;虎石竜典;川口崇;河地茂行;奥山清;畝崎榮;島津元秀;永味千枝,堀英生,菊池千草,竹内正義,松永民秀;Andre Kamkin;Hiroshi Yamazaki
- 通讯作者:Hiroshi Yamazaki
Species, Ethnic, and Individual Differences in Human Drug-metabolizing Cytochrome P450 Enzymes
人类药物代谢细胞色素 P450 酶的物种、民族和个体差异
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:Inoue;H;IIhara;A;Takahashi;H;Shimada;I;Ishida;I and Maeda;Y;Hiroshi Yamazaki
- 通讯作者:Hiroshi Yamazaki
P450 Based DDI and Clinical Significance: Genotyping and Phenotyping
基于 P450 的 DDI 和临床意义:基因分型和表型分析
- DOI:
- 发表时间:2013
- 期刊:
- 影响因子:0
- 作者:グリミル・ムヒタル;竹内裕紀;畝崎榮;平野俊彦;島津元秀;Hiroshi Yamazaki
- 通讯作者:Hiroshi Yamazaki
mpact of human drug-metabolizing enzymes in drug development
人类药物代谢酶对药物开发的影响
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:Shimizu;Y;Isoda;K;Tezuka;E;Yufu;T;Nagai;Y;Ishida;I;Tezuka M.;Hiroshi Yamazaki
- 通讯作者:Hiroshi Yamazaki
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YAMAZAKI Hiroshi其他文献
YAMAZAKI Hiroshi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YAMAZAKI Hiroshi', 18)}}的其他基金
Relevance to bioactivation and toxicity of thalidomide, pomalidomide, and lenalidomide by human cytochrome P450 3A enzymes in cultured placental cells and humanized-liver mice
培养胎盘细胞和人源化肝小鼠中人细胞色素 P450 3A 酶与沙利度胺、泊马度胺和来那度胺生物活性和毒性的相关性
- 批准号:
17K08425 - 财政年份:2017
- 资助金额:
$ 3.49万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanisms of resistance to molecularly targeted drugs for oral squamous cell carcinoma and investigation of countermeasures
口腔鳞癌分子靶向药物耐药机制及对策研究
- 批准号:
16K11732 - 财政年份:2016
- 资助金额:
$ 3.49万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of Effective Markers for Resistance of Oral Squamous Cell Carcinoma to Molecular-targeting Drugs
口腔鳞状细胞癌分子靶向药物耐药性有效标志物的开发
- 批准号:
25463120 - 财政年份:2013
- 资助金额:
$ 3.49万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
evaluationofeffectivenessoftheobjectiveexaminationforautism indeafchildren
聋儿自闭症客观检查效果评价
- 批准号:
22791642 - 财政年份:2010
- 资助金额:
$ 3.49万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Role of cancer stem cells related molecules in oral squamous cell carcinoma
肿瘤干细胞相关分子在口腔鳞癌中的作用
- 批准号:
22592246 - 财政年份:2010
- 资助金额:
$ 3.49万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanism of chemical-induced toxicity in fetal livers
化学品致胎儿肝脏毒性的分子机制
- 批准号:
17390034 - 财政年份:2005
- 资助金额:
$ 3.49万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Molecular Mechanisms of Toxic Expression Induced by Endocrine Disruptors via AHR
内分泌干扰物通过 AHR 诱导毒性表达的分子机制
- 批准号:
15390040 - 财政年份:2003
- 资助金额:
$ 3.49万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Study on the separation of rac and meso isomers and the reactivity of group 4 bridged metallocene complexes
外消旋和内消旋异构体的分离及第4族桥联茂金属配合物的反应性研究
- 批准号:
11640544 - 财政年份:1999
- 资助金额:
$ 3.49万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PREDICTION OF DRUG DISPOSITION BY HUMAN DRUG METABOLIZING ENZYMES
通过人体药物代谢酶预测药物分布
- 批准号:
11557191 - 财政年份:1999
- 资助金额:
$ 3.49万 - 项目类别:
Grant-in-Aid for Scientific Research (B).
Creation of Substitution Labile Pyrazolylborate Metal Complexes
取代不稳定的吡唑基硼酸盐金属配合物的制备
- 批准号:
09640675 - 财政年份:1997
- 资助金额:
$ 3.49万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似海外基金
ゲノム編集マウスを用いたサリドマイド催奇性メカニズムの解析
使用基因组编辑小鼠分析沙利度胺致畸机制
- 批准号:
23K14171 - 财政年份:2023
- 资助金额:
$ 3.49万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
サリドマイドの副作用である催奇形性を回避する標的タンパク質分解誘導剤の開発
开发一种靶向蛋白质降解诱导剂,可避免致畸性(沙利度胺的副作用)
- 批准号:
23KJ1669 - 财政年份:2023
- 资助金额:
$ 3.49万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of novel thalidomide derivatives that avoid teratogenicity of targeted protein degradation inducers
开发新型沙利度胺衍生物,避免靶向蛋白质降解诱导剂的致畸性
- 批准号:
22K20713 - 财政年份:2022
- 资助金额:
$ 3.49万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Elucidation of the therapeutic mechanisms of IMiDs
阐明 IMiD 的治疗机制
- 批准号:
21H02955 - 财政年份:2021
- 资助金额:
$ 3.49万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of analysis method for thalidomide-dependent interactome using proximity-dependent biotinylation enzyme
使用邻近依赖性生物素化酶开发沙利度胺依赖性相互作用组分析方法
- 批准号:
21K15076 - 财政年份:2021
- 资助金额:
$ 3.49万 - 项目类别:
Grant-in-Aid for Early-Career Scientists